LLY Eli Lilly: Plans To Submit Biologics License Application For Retatrutide To FDA In RESULTS: Q1, Q1 2027, Eli Lilly: Plans To Submit Biol
LLY Eli Lilly: Plans To Submit Biologics License Application For Retatrutide To FDA In RESULTS: Q1, Q1 2027, Eli Lilly: Plans To Submit Biologics License Application For Retatrutide To FDA In Earnings Notes:, Reports positive topline results from triumph-2 & triumph-3, two pivotal phase 3 trials evaluating retatrutide, In triumph-2, adults with obesity or overweight & type 2 Diabetes lost up to average of 49.6 lbs (20.8%) at 80 weeks, In triumph-2 & triumph-3 studies, retatrutide met primary endpoint, In triumph-3, adults with severe obesity & established cardiovascular disease lost up to average of 55.8 lbs (22.6%) at 80 weeks
Story updates
LLY Eli Lilly: Plans To Submit Biologics License Application For Retatrutide To FDA In RESULTS: Q1, Q1 2027, Eli Lilly: Plans To Submit Biologics License Application For Retatrutide To FDA In Earnings Notes:, Reports positive topline results from triumph-2 & triumph-3, two pivotal phase 3 trials evaluating retatrutide, In triumph-2, adults with obesity or overweight & type 2 Diabetes lost up to average of 49.6 lbs (20.8%) at 80 weeks, In triumph-2 & triumph-3 studies, retatrutide met primary endpoint, In triumph-3, adults with severe obesity & established cardiovascular disease lost up to average of 55.8 lbs (22.6%) at 80 weeks